News
Switzerland Has an Advanced Pharmaceutical Market and Per-Capita Expenditure Is Among the Highest in the World at an Estimated US$743.4 in 2006
DUBLIN, Ireland-(Business Wire)-March 14, 2008 - Research and Markets (http://www.researchandmarkets.com/reports/c85987) has announced the addition of Switzerland Pharmaceuticals & Healthcare Report Q1 2008 to their offering.
The Switzerland Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Switzerland's pharmaceuticals and healthcare industry.
Switzerland has an advanced pharmaceutical market and per-capita expenditure is among the highest in the world at an estimated US$743.4 in 2006. Consumption centres around patented pharmaceuticals, with Switzerland providing a ready market for cutting-edge therapies. Meanwhile, high-levels of out-of-pocket expenditure have resulted in the development of a mature and competitive consumer health sector. Overall market growth should expand at a CAGR of 5.73% over the forecast period to reach a value of US$7.69bn.
In the latest quarter, most market activity has been centred around the major domestic players, with Novartis having an especially busy few months. The multinational has recently announced restructuring plans involving shedding 2,500 jobs, or 2.5% of its workforce, as it hopes to achieve savings of US$1.6bn a year until 2010. Meanwhile, Sandoz, Novartis' generics arm, has announced that it is to launch a generic version of biotech anaemia treatment epoetin alfa (EPO), the primary ingredient in US-based Amgens blockbuster Epogen. The author views the launch as a major step forward for the rapidly growing biosimilars industry.
In terms of M&A activity, the major deal saw Swiss pharmaceutical producer and wholesaler Galenica acquire Canadian biotech Aspreva in a deal worth US$900mn. The purchase is one of the largest ever in the Canadian pharmaceutical sector and has provided a ringing endorsement for Canada's biotech industry, often criticised as a difficult environment to work in, while also highlighting the continual interest of the major Swiss players in snapping up biotech assets.
Meanwhile, Switzerland takes first place in the author's revised Business Environment Rankings for the Western European region. We have completely overhauled the methodology giving greater weight to regulatory factors affecting the drug market, while utilising a more nuanced analysis of country-specific economic and political factors. Switzerland's position derives mainly from its excellent regulatory system and high per-capita expenditure.
Content Outline:
Executive Summary
Switzerland Pharmaceuticals And Healthcare Industry SWOT
Switzerland Political SWOT
Switzerland Economic SWOT
Pharmaceutical Business Environment Ratings
Pharmaceutical Ratings - Revised Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Regional Pharmaceutical Business Environment Ranking
Table: Business Environment Rankings
Limits To Potential Returns
Risks To Realisation Of Returns
Western Europe Overview
Switzerland - Market Summary
Regulatory Regime
Intellectual Property Developments
Pricing And Reimbursement Issues
Table: A Comparison of Medicine Prices in Western Europe
Industry Developments
Healthcare Sector
Pharmaceutical Sector
Table: Domestic Pharmaceutical Companies in Switzerland, 2005
Domestic Industry
Multinational Sector
Roche Boosted By Biotechnology
Novartis Announces Restructuring
Research And Development Sector
Hospital Sector
Pharmacy Sector
Biotechnology Sector
Industry Forecast Scenario
Overall Market Forecast
Table: Swiss Pharmaceutical Expenditure Indicators
Key Growth Factors - Industry
Table: Swiss Health Expenditure Indicators
Key Growth Factors - Macroeconomic
Table: Switzerland - Economic Forecasts
Prescription Market Forecast
Table: Swiss Prescription Drugs Market Forecast Indicators (US$mn unless otherwise stated)
OTC Market Forecast
Table: Swiss OTC Market Forecast Indicators (US$mn unless otherwise stated)
Switzerland Pharmaceuticals & Healthcare Report Q1 2008
Generics And Branded Market Forecasts
Table: Swiss Generics And Branded Market Forecast In 55
Export/Import Forecasts
Table: Swiss Pharmaceuticals Exports And Imports Forecast Indicators (US$mn)
Key Risks To our Forecast Scenario
Competitive Landscape
Company Profiles
Leading Multinational Manufacturers
GlaxoSmithKline (GSK)
Pfizer
Sanofi-Aventis
Merck & Co
Indigenous Manufacturers
Novartis
Roche
Serono
Our Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Sources
Companies Mentioned:
- GlaxoSmithKline (GSK)
- Pfizer
- Sanofi-Aventis
- Merck & Co
- Novartis
- Roche
- Serono
For more information visit http://www.researchandmarkets.com/reports/c85987.
Search Our News Using Google Search
Can't find what you want? Try using Google:
